{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:18:57Z","timestamp":1778746737814,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10072-025-08680-z","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T03:26:31Z","timestamp":1765941991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5352-4506","authenticated-orcid":false,"given":"Rui","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5953-5016","authenticated-orcid":false,"given":"Liming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6523-7488","authenticated-orcid":false,"given":"Huishan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"8680_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"8680_CR2","doi-asserted-by":"publisher","first-page":"Itc81","DOI":"10.7326\/aitc202406180","volume":"177","author":"AL Crawford","year":"2024","unstructured":"Crawford AL, Laiteerapong N (2024) Type 2 diabetes. Ann Intern Med 177(6):Itc81\u2013itc96. https:\/\/doi.org\/10.7326\/aitc202406180","journal-title":"Ann Intern Med"},{"key":"8680_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314631","author":"I Forzano","year":"2022","unstructured":"Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G (2022) Tirzepatide: a systematic update. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232314631","journal-title":"Int J Mol Sci"},{"issue":"11","key":"8680_CR4","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 45(11):2753\u20132786. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"issue":"6","key":"8680_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2337\/dc23-2356","volume":"47","author":"P Zeitler","year":"2024","unstructured":"Zeitler P, Galindo RJ, Davies MJ, Bergman BK, Thieu VT, Nicolay C et al (2024) Early-onset type 2 diabetes and Tirzepatide treatment: a post hoc analysis from the SURPASS clinical trial program. Diabetes Care 47(6):1056\u20131064. https:\/\/doi.org\/10.2337\/dc23-2356","journal-title":"Diabetes Care"},{"issue":"3","key":"8680_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28(3):591\u2013598. https:\/\/doi.org\/10.1038\/s41591-022-01707-4","journal-title":"Nat Med"},{"key":"8680_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.amjcard.2022.03.042","volume":"173","author":"D Patoulias","year":"2022","unstructured":"Patoulias D, Doumas M, Papadopoulos C (2022) Meta-analysis assessing the effect of Tirzepatide on the risk for atrial fibrillation in patients with type 2 diabetes mellitus. Am J Cardiol 173:157\u2013158. https:\/\/doi.org\/10.1016\/j.amjcard.2022.03.042","journal-title":"Am J Cardiol"},{"issue":"1","key":"8680_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 21(1):169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"8680_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819","author":"AM Jastreboff","year":"2024","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S et al (2024) Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2410819","journal-title":"N Engl J Med"},{"key":"8680_CR10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"8680_CR11","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"issue":"A","key":"8680_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45(A):139\u2013145. https:\/\/doi.org\/10.1016\/j.cct.2015.09.002","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"8680_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H et al (2022) Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6):534\u2013545. https:\/\/doi.org\/10.1001\/jama.2022.0078","journal-title":"JAMA"},{"issue":"10313","key":"8680_CR14","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/s0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811\u20131824. https:\/\/doi.org\/10.1016\/s0140-6736(21)02188-7","journal-title":"Lancet"},{"issue":"6","key":"8680_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"issue":"6","key":"8680_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X et al (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 22(6):938\u2013946. https:\/\/doi.org\/10.1111\/dom.13979","journal-title":"Diabetes Obes Metab"},{"issue":"10160","key":"8680_CR17","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/s0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180\u20132193. https:\/\/doi.org\/10.1016\/s0140-6736(18)32260-8","journal-title":"Lancet"},{"issue":"6","key":"8680_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M, Kim J, Huo L, Du L et al (2023) Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med 29(6):1500\u20131510. https:\/\/doi.org\/10.1038\/s41591-023-02344-1","journal-title":"Nat Med"},{"issue":"10402","key":"8680_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/s0140-6736(23)01200-x","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, Roux CW, Sattar N, Aizenberg D et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402(10402):613\u2013626. https:\/\/doi.org\/10.1016\/s0140-6736(23)01200-x","journal-title":"Lancet"},{"issue":"6","key":"8680_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/s2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ et al (2022) Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 10(6):418\u2013429. https:\/\/doi.org\/10.1016\/s2213-8587(22)00085-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"8680_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/s2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y (2022) Efficacy and safety of Tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10(9):623\u2013633. https:\/\/doi.org\/10.1016\/s2213-8587(22)00188-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10300","key":"8680_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/s0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K et al (2021) Once-weekly Tirzepatide versus once-daily insulin degludec as add-on to Metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398(10300):583\u2013598. https:\/\/doi.org\/10.1016\/s0140-6736(21)01443-4","journal-title":"Lancet"},{"issue":"17","key":"8680_CR23","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Rodbard HW, Tof\u00e9 S, Sears E, Huh R et al (2023) Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA 330(17):1631\u20131640. https:\/\/doi.org\/10.1001\/jama.2023.20294","journal-title":"JAMA"},{"issue":"10295","key":"8680_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143\u2013155. https:\/\/doi.org\/10.1016\/s0140-6736(21)01324-6","journal-title":"Lancet"},{"issue":"Pt 2","key":"8680_CR25","doi-asserted-by":"publisher","first-page":"113499","DOI":"10.1016\/j.intimp.2024.113499","volume":"143","author":"Y Xia","year":"2024","unstructured":"Xia Y, Jin J, Sun Y, Kong X, Shen Z, Yan R et al (2024) Tirzepatide\u2019s role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance. Int Immunopharmacol 143(Pt 2):113499. https:\/\/doi.org\/10.1016\/j.intimp.2024.113499","journal-title":"Int Immunopharmacol"},{"key":"8680_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102586","author":"T Bulum","year":"2022","unstructured":"Bulum T (2022) Nephroprotective properties of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10102586","journal-title":"Biomedicines"},{"key":"8680_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf006","author":"R Shang","year":"2025","unstructured":"Shang R, Rodrigues B (2025) Cardioprotective effects of a \u201ctwincretin\u201d drug tirzepatide in heart failure following myocardial infarction. Cardiovasc Res. https:\/\/doi.org\/10.1093\/cvr\/cvaf006","journal-title":"Cardiovasc Res"},{"issue":"4","key":"8680_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","volume":"19","author":"R Hammoud","year":"2023","unstructured":"Hammoud R, Drucker DJ (2023) Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 19(4):201\u2013216. https:\/\/doi.org\/10.1038\/s41574-022-00783-3","journal-title":"Nat Rev Endocrinol"},{"key":"8680_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101550","volume":"64","author":"RJ Samms","year":"2022","unstructured":"Samms RJ, Zhang G, He W, Ilkayeva O, Droz BA, Bauer SM et al (2022) Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol Metab 64:101550. https:\/\/doi.org\/10.1016\/j.molmet.2022.101550","journal-title":"Mol Metab"},{"issue":"1","key":"8680_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02203-4","volume":"23","author":"F Taktaz","year":"2024","unstructured":"Taktaz F, Scisciola L, Fontanella RA, Pesapane A, Ghosh P, Franzese M et al (2024) Evidence that Tirzepatide protects against diabetes-related cardiac damages. Cardiovasc Diabetol 23(1):112. https:\/\/doi.org\/10.1186\/s12933-024-02203-4","journal-title":"Cardiovasc Diabetol"},{"key":"8680_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.amjcard.2022.07.003","volume":"181","author":"D Patoulias","year":"2022","unstructured":"Patoulias D, Papadopoulos C, Fragakis N, Doumas M (2022) Updated meta-analysis assessing the cardiovascular efficacy of Tirzepatide. Am J Cardiol 181:139\u2013140. https:\/\/doi.org\/10.1016\/j.amjcard.2022.07.003","journal-title":"Am J Cardiol"},{"issue":"3","key":"8680_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/23969873241234238","volume":"9","author":"MI Stefanou","year":"2024","unstructured":"Stefanou MI, Theodorou A, Malhotra K, de Aguiar Sousa D, Katan M, Palaiodimou L et al (2024) Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis. Eur Stroke J 9(3):530\u2013539. https:\/\/doi.org\/10.1177\/23969873241234238","journal-title":"Eur Stroke J"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08680-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08680-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08680-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:05:26Z","timestamp":1773068726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08680-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["8680"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08680-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis was based on former studies and ethical approval was not required in this meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Informed consent statement"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of interest"}}],"article-number":"10"}}